| Fund |
Firm |
Onset |
AUM |
| TCG Crossover Fund I LP |
TCG Crossover Management LLC |
2021 |
1,914.1 M |
| Samsara Biocapital LP |
Samsara Biocapital LLC |
2017 |
1,900.0 M |
| Braidwell Partners LP |
Braidwell LP |
2021 |
1,889.4 M |
| Valley Forge Capital LP |
Valley Forge Capital Management LP |
2012 |
1,827.8 M |
| Anson Investments Master Fund LP |
Anson Funds Management LP |
2012 |
1,790.5 M |
| Condire Resource Master Partnership LP |
Condire Management LP |
2018 |
1,744.4 M |
| Irenic Capital Evergreen Master Fund LP |
Irenic Capital Management LP |
2022 |
1,743.2 M |
| TCG Crossover Fund II LP |
TCG Crossover Management LLC |
2024 |
1,713.9 M |
| Affinity Healthcare Fund LP |
Affinity Asset Advisors LLC |
2021 |
1,691.1 M |
| Multicoin Capital Master Fund LP |
Multicoin Capital Management LLC |
2019 |
1,677.6 M |
| GCM Grosvenor Special Opportunities Master Fund Ltd |
GCM Grosvenor LP |
2015 |
1,669.6 M |
| Haveli Investments Software Fund Cayman I LP |
Haveli Investment Management LLC |
2023 |
1,643.2 M |
| UCF Fixed Income Fund LP |
United States Steel and Carnegie Pension Fund |
2016 |
1,642.8 M |
| Orion Mine Finance Fund II LP |
Orion Resource Partners USA LP |
2016 |
1,625.7 M |
| Quinn Opportunities Master LP |
Quinn Opportunity Partners LLC |
2019 |
1,622.1 M |
| 23 Patient Square Equity Partners II-A LP |
Patient Square Capital LP |
2025 |
1,510.7 M |
| 22 Patient Square Equity Partners II LP |
Patient Square Capital LP |
2025 |
1,510.7 M |
| Echinus Partners LP |
Echinus Advisors LLC |
2013 |
1,392.1 M |
| Frazier Life Sciences XII LP |
Frazier Life Sciences Management LP |
2025 |
1,350.6 M |
| Clearlake Capital Partners V Offshore LP |
Clearlake Capital Group LP |
2018 |
1,261.7 M |
| Saba Capital Bluebird Fund Ltd |
Saba Capital Management LP |
2022 |
1,195.4 M |
| Sofinnova Bioequities Enhanced Master Fund LP |
Sofinnova Investments Inc |
2023 |
1,194.9 M |
| ADAR1 Partners LP |
ADAR1 Capital Management LLC |
2024 |
1,179.9 M |
| GCM Grosvenor Strategic Credit LP |
GCM Grosvenor LP |
2020 |
1,134.6 M |
| Frazier Life Sciences Xi LP |
Frazier Life Sciences Management LP |
2022 |
1,107.8 M |
| EMS Opportunity Ltd |
EMS Capital LP |
2012 |
1,065.1 M |
| Whitefort Capital Master Fund LP |
Whitefort Capital Management LP |
2017 |
1,051.1 M |
| Baronx II LP |
Baron Capital Management Inc |
2025 |
1,048.6 M |
| Concentric 150 Fund LP |
Concentric Capital Strategies LP |
2024 |
1,036.1 M |
| Oncology Impact Fund 2 LP |
MPM Asset Management LLC |
2020 |
1,002.8 M |
| Khrom Investments Fund LP |
Khrom Capital Management LLC |
2014 |
980.6 M |
| Caledonia Co-Invest Master Fund LP |
Caledonia US LP |
2017 |
956.8 M |
| Trails Edge Biotechnology Master Fund LP |
Trails Edge Capital Partners LP |
2025 |
933.4 M |
| Fourthstone Master Opportunity Fund Ltd |
Fourthstone LLC |
2019 |
929.3 M |
| Row Diversified Fund LP |
Row Asset Management LLC |
2013 |
920.0 M |
| SilverArc Capital Alpha Fund II LP |
SilverArc Capital Management LLC |
2019 |
881.4 M |
| Saba Capital CEF Opportunities 1 Ltd |
Saba Capital Management LP |
2016 |
876.3 M |
| Timucuan Fund LP |
Timucuan Asset Management Inc |
2012 |
871.5 M |
| Maxima Fund IV LP |
Saddle Point Management LP |
2025 |
850.4 M |
| Sphera Master Fund LP |
Sphera Funds Management Ltd |
2021 |
849.7 M |
| KG Investments Fund LLC |
KG Funds Management LLC |
2012 |
844.4 M |
| Haveli VC Gaming Fund I LP |
Haveli Investment Management LLC |
2022 |
826.1 M |
| Castle Advisers LP |
Baron Capital Management Inc |
2012 |
818.5 M |
| Alta Fox Opportunities Fund LP |
Alta Fox Capital Management LLC |
2020 |
815.1 M |
| Caligan Partners Master Fund LP |
Caligan Partners LP |
2022 |
812.0 M |
| Prelude Opportunity Fund LP |
Prelude Capital Management LLC |
2012 |
793.5 M |
| Coastlands Capital Partners LP |
Coastlands Capital LP |
2025 |
785.0 M |
| Frazier Life Sciences X LP |
Frazier Life Sciences Management LP |
2020 |
781.2 M |
| MYDA Advantage LP |
MYDA Advisors LLC |
2014 |
763.8 M |
| EXPO Health Sciences Master Fund LP |
EXPO Capital Management LLC |
2012 |
761.5 M |
Prev | Page 2 | Next
|